Polio vaccine shows promise against COVID-19 in african trial
NCT ID NCT04445428
First seen Apr 14, 2026 · Last updated May 01, 2026 · Updated 3 times
Summary
This study tested whether giving the oral polio vaccine (OPV) to adults over 50 in Guinea-Bissau could lower their risk of getting sick or dying from COVID-19. About 3,700 people took part, with half receiving OPV and half receiving no vaccine. The idea is that live vaccines like OPV can boost the immune system in a general way, possibly fighting off other viruses like SARS-CoV-2. The main goal was to see if OPV reduced hospital visits, infections, or deaths over six months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Bandim Health Project
Bissau, Guinea-Bissau
Conditions
Explore the condition pages connected to this study.